Literature DB >> 28947021

Medical lung volume reduction for severe emphysema: A review.

Kalliopi Aggelou1, Nikolaos Siafakas2.   

Abstract

Lung hyperinflation is the main pathophysiological mechanism significantly reducing the Quality of Life (QoL)and contributing to increased morbidity and mortality of the emphysematous patients. Therefore, the prime aim of the management of those patients is the deflation of their lungs. There are a number of treatments proven effective to reduce hyperinflation, such as,pharmacotherapy (bronchodilators/deflators), rehabilitation and surgical volume reduction. Recently, methods to reduce lung volume by a bronchoscopic approach had been developed. We review these methods and in particular the endobronchial valves, coils and the sclerosing therapies and provide the current status, as well as, an algorithm of selection of the appropriate patients. We conclude that further large studies are needed in order to verify the effectiveness of these methods and identify the appropriate group of patients that can be benefit by each of these bronchoscopic techniques.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COPD; Chronic Obstructive Pulmonary Disease; Endobronchial coil; Endobronchial valve; Lung deflation; Lung hyperinflation; Sclerosing therapy

Mesh:

Substances:

Year:  2017        PMID: 28947021     DOI: 10.1016/j.rmed.2017.08.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

Review 1.  Bronchoscopic lung volume reduction: recent updates.

Authors:  Anuradha Ramaswamy; Jonathan Puchalski
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  Bronchoscopic lung volume reduction procedures for emphysema: A network meta-analysis.

Authors:  Wu Xu; Junyi Wang; Xiang He; Junlan Wang; Dehong Wu; Guoping Li
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

3.  The efficacy of continuous nursing care for patients with chronic obstructive pulmonary disease: A randomized controlled trial protocol.

Authors:  Xue Guo; Fengmin Men; Xingfen Han; Zhenying Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.